• New Dexcom product with 15-day wear, a cash-pay option and a tailored software experience for people who don’t use insulin is expected to launch in the U.S. in 2024
• Access and availability of Dexcom CGM is expanding globally, with Dexcom G7 now available in 14 countries and the recent launch of Dexcom ONE in Argentina marking the company’s first entrance into Latin America
• Private payers in the U.S. are following Medicare’s lead faster than expected; 60% of commercial insurers now cover Dexcom CGM for people with Type 2 diabetes on basal insulin
• In addition, new projections estimate 3-4 million people in the US have a history of problematic hypoglycemia, and many of them are now covered for Dexcom CGM through Medicare
• This weekend, ADA conference symposia, posters and presentations will reinforce the safety, industry-leading accuracy, connectivity and affordability of Dexcom CGM
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people living with diabetes, announced today its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured at the 83rd Scientific Sessions of the American Diabetes Association being held June 23-26 in San Diego. Read more >
